Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


In Brief: Summit Technology v. Chiron Technolas GmbH

This article was originally published in The Gray Sheet

Executive Summary

Summit Technology v. Chiron Technolas GmbH: Chiron Technolas appeals German court ruling that the firm's Keracor 116 and Schwind GmbH's Keratom ophthalmic excimer laser systems infringe a Summit patent ("The Gray Sheet" Sept. 4, p. 14). Chiron Technolas is prohibited from manufacturing, selling or using the laser systems in Germany following the posting of a bond by Summit that was necessary for enforcement of an injunction issued by the German court. In addition to the appeal, Chiron Technolas has also filed a nullity action with the German patent office, Summit states. Schwind also plans to file an appeal. Coherent, which distributes the Schwind laser, states that no interruptions in product availability are anticipated since its laser can be offered with a newly developed optical delivery system that does not infringe "whenever it becomes necessary to do so," Coherent states...

You may also be interested in...

Italy Round-Up: Mylan And Polifarma Strike Deal, OTC Market Stable, Cholesterol-Lowering Probiotic Launch

The latest news from Italy's OTC and supplements markets, including the latest sales figures, business deals, product launches, ad regulation and local association activities.

Sandoz Pledges Price Stability Amid Coronavirus

Sandoz CEO Richard Saynor has pledged that the company will ensure stable pricing for essential coronavirus-related medicines amid concerns over how the outbreak will affect the supply chain.

Executives On The Move: Comings And Goings At Atara Biothera And Pfizer, Along With A Promotion At Domainex

T-cell immunotherapy firm Atara Biotherapeutics decides on a chief commercial officer and Pfizer oncology R&D head leaves for CSO spot at Vividion Therapeutics. Also, COO of UK drug discovery CRO Domainex is set to climb to CEO position.




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts